UA40590C2 - Похідні оксазоліденону, спосіб їх одержання , фармацевтична композиція та спосіб її одержання - Google Patents

Похідні оксазоліденону, спосіб їх одержання , фармацевтична композиція та спосіб її одержання

Info

Publication number
UA40590C2
UA40590C2 UA94085682A UA94085682A UA40590C2 UA 40590 C2 UA40590 C2 UA 40590C2 UA 94085682 A UA94085682 A UA 94085682A UA 94085682 A UA94085682 A UA 94085682A UA 40590 C2 UA40590 C2 UA 40590C2
Authority
UA
Ukraine
Prior art keywords
compounds
preparing
cell
oxazolidinone
derivatives
Prior art date
Application number
UA94085682A
Other languages
English (en)
Russian (ru)
Inventor
Хорст Юрасцук
Петер РАДДАТЦ
Ханс Вурцигєр
Ханс Вурцигер
Гвідо Мєльзєр
Гвидо Мельзер
Сабіна Бернотат-Данієловскі
Сабина Бернотат-Даниеловски
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of UA40590C2 publication Critical patent/UA40590C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

Винахід належить до похідних оксазолідінону формули (I) В основу винаходу покладено завдання одержання нових сполук з цінними властивостями, зокрема таких, які можна застосовувати для приготування лікарських засобів. Знайдено, що сполуки формули (I), а також їх сольвати і солі при добрій сумісності мають цінні фармакологічні властивості. Особливо вони пригнічують зв’язування фібріногену, фібронектину і фактора Віллебранда з рецептором фібріногену тромбоцитів (глікопротеїн Пб/Ша), як також зв’язування їх та інших адгезивних протеїнів, як вітронектин, коллаген и ламінін, з відповідними рецепторами на поверхні різних типів клітин. Сполуки таким чином впливають на взаємодію клітина- клітина і клітина -матриця. Особливо вони перещкоджають утворенню. тромбоцитних тромбів і тому можуть застосовуватись для лікування тромбозів, апоплексії, інфаркту серця, запалень, артеріосклерозу. Далі, сполуки діють на пухлинні клітини, тим, що вони пригнічують їх метастазування. Таким чином їх також можна застосовувати як протипухлинні засоби.
UA94085682A 1993-09-23 1994-08-01 Похідні оксазоліденону, спосіб їх одержання , фармацевтична композиція та спосіб її одержання UA40590C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4332384A DE4332384A1 (de) 1993-09-23 1993-09-23 Adhäsionsrezeptor-Antagonisten III

Publications (1)

Publication Number Publication Date
UA40590C2 true UA40590C2 (uk) 2001-08-15

Family

ID=6498425

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94085682A UA40590C2 (uk) 1993-09-23 1994-08-01 Похідні оксазоліденону, спосіб їх одержання , фармацевтична композиція та спосіб її одержання

Country Status (21)

Country Link
US (3) US5561148A (uk)
EP (1) EP0645376B1 (uk)
JP (1) JPH07179441A (uk)
KR (1) KR100347849B1 (uk)
CN (1) CN1052227C (uk)
AT (1) ATE178599T1 (uk)
AU (1) AU682050B2 (uk)
CA (1) CA2132579A1 (uk)
CZ (1) CZ288819B6 (uk)
DE (2) DE4332384A1 (uk)
DK (1) DK0645376T3 (uk)
ES (1) ES2132295T3 (uk)
GR (1) GR3030512T3 (uk)
HU (1) HU217980B (uk)
NO (1) NO305203B1 (uk)
PL (1) PL180462B1 (uk)
RU (1) RU2125560C1 (uk)
SK (1) SK282134B6 (uk)
TW (1) TW381086B (uk)
UA (1) UA40590C2 (uk)
ZA (1) ZA947405B (uk)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313411A1 (de) * 1993-04-23 1994-10-27 Basf Ag 3-Halogen-3-hetarylcarbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DE4429461A1 (de) * 1994-08-19 1996-02-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
ATE170179T1 (de) * 1994-11-02 1998-09-15 Merck Patent Gmbh Adhäsionsrezeptor-antagonisten
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
WO1996023788A1 (en) * 1995-02-03 1996-08-08 Pharmacia + Upjohn Company Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19601265A1 (de) 1996-01-16 1997-07-17 Bayer Ag 2-Oxo- und 2-Thio-1,2-dihydrochinolinyl-oxazolidinone
DE19601627A1 (de) * 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
JP2000516596A (ja) * 1996-07-25 2000-12-12 バイオジェン，インコーポレイテッド 細胞接着インヒビター
EP0928194A4 (en) * 1996-08-29 2001-01-17 Merck & Co Inc COMPOSITIONS AND METHODS FOR ADMINISTERING INTEGRIN RECEPTOR ANTAGONISTS
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
PL345162A1 (en) 1998-06-05 2001-12-03 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
JP2002533416A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−２インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
BR0308018A (pt) * 2002-02-28 2005-01-04 Astrazeneca Ab Composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo, pró-droga, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hirolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2579374A1 (en) 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2624310C (en) 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
AU2009206658A1 (en) * 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. 3,5-substituted-1,3-oxazolidin-2-one derivatives
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
US4602093A (en) * 1984-02-08 1986-07-22 Merck & Co., Inc. Novel substituted imidazoles, their preparation and use
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
HU220601B1 (hu) * 1992-04-30 2002-03-28 Taiho Pharmaceutical Co. Ltd. Fenoxi-alkil-oxazolidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4324393A1 (de) * 1993-07-21 1995-01-26 Merck Patent Gmbh 4-Aryloxy- und 4-Arylthiopiperidinderivate
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW286317B (uk) * 1993-12-13 1996-09-21 Hoffmann La Roche
TW363051B (en) * 1995-08-31 1999-07-01 Mitsui Toatsu Chemicals Substituted amidine derivatives and platelet aggregation inhibitor containing the same

Also Published As

Publication number Publication date
US5561148A (en) 1996-10-01
JPH07179441A (ja) 1995-07-18
CZ288819B6 (cs) 2001-09-12
AU682050B2 (en) 1997-09-18
AU7305094A (en) 1995-04-06
HU9402724D0 (en) 1994-12-28
US6028090A (en) 2000-02-22
ATE178599T1 (de) 1999-04-15
NO943523L (no) 1995-03-24
KR950008493A (ko) 1995-04-17
CN1106806A (zh) 1995-08-16
SK282134B6 (sk) 2001-11-06
TW381086B (en) 2000-02-01
US5723480A (en) 1998-03-03
HU217980B (hu) 2000-05-28
RU94034124A (ru) 1996-07-10
NO305203B1 (no) 1999-04-19
RU2125560C1 (ru) 1999-01-27
DE4332384A1 (de) 1995-03-30
ES2132295T3 (es) 1999-08-16
CA2132579A1 (en) 1995-03-24
NO943523D0 (no) 1994-09-22
ZA947405B (en) 1995-05-15
DE59408068D1 (de) 1999-05-12
PL180462B1 (pl) 2001-02-28
HUT71233A (en) 1995-11-28
SK112194A3 (en) 1995-05-10
EP0645376B1 (de) 1999-04-07
KR100347849B1 (ko) 2002-11-16
PL305144A1 (en) 1995-04-03
CN1052227C (zh) 2000-05-10
DK0645376T3 (da) 1999-10-18
EP0645376A1 (de) 1995-03-29
GR3030512T3 (en) 1999-10-29
CZ224794A3 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
UA40590C2 (uk) Похідні оксазоліденону, спосіб їх одержання , фармацевтична композиція та спосіб її одержання
CA2093770A1 (en) Aspartic acid derivatives, their preparation and use
HUT58288A (en) Process for producing heterocyclic guanidines and pharmaceutical compositions containing them
EP0236987A3 (en) Chemically modified protein and production thereof
DE59407303D1 (de) Metallocene und ihre Verwendung als Katalysatoren
GR3024027T3 (en) Benzimidazoles, medicaments containing them and process for their preparation
DE69006811D1 (de) Lipidverbindungen abgeleitet von Sphingosinen, Verfahren zu deren Herstellung und Verwendung, besonders in der Kosmetik und Dermopharmazie.
PL302069A1 (en) Piperazine derivatives, method of obtaining them as well as pharmaceutical preparation and method of making same
FR2336935A1 (fr) Nouvelles pyrimidones, leur procede de preparation et leur application
ATE305000T1 (de) Sysntheseverfahren zur herstellung von indolylquinonen und mono- und bis-indolylquinone, die durch das verfahren hergestellt sind
ATE303437T1 (de) Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
HU903013D0 (en) Process for the preparation of novel aryl-sulfonamides and pharmaceutical compositions containing them
PT85187A (fr) Procede de preparation de systemes pour adhesives thermofusibles reticulables et procede de collage correspondant
IL97158A0 (en) Side-chain homologous vitamin d derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
PT78161A (de) Verfahren zur herstellung von 4-amino-6,7-dimethoxy-2-<4-(furo--2-yl)-piperazin-1-yl>-chinazolin und dessen physiologisch annehmabarer salze
EP0810215A4 (en) NOVEL BENZAMIDINE DERIVATIVES AND THEIR MEDICINAL COMPOSITION
EP0339834A3 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE69900214D1 (de) Herstellung von (s)-n-tert-butyl-1,2,3,4-tetrahydroisoquinolin-3-carboxamid
ES8601148A1 (es) Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos.
ZA919205B (en) New pyridyl derivatives, pharmaceutical compositions containing these compounds and processes for preparing them.
ES8402287A1 (es) Procedimiento de obtencion de nuevas carboxamidoguanidinas.
EP1227083A4 (en) 3-AMINOPIPERIDE DERIVATIVES AS INTEGRIN- $ g (a) v $ g (b) 3-ANTAGONISTS
FI843850A0 (fi) Nya 2,6-dioxsa-bicyklo-/2,2,2/-oktan-7-yl-acetaldehyder.
EP0272909A3 (en) Synthesis of aminothioacetamides
Kiely et al. Polyhydroxypolyamides and process for making same